Vivus Inc (VVUS) 3.78 $VVUS
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...
Business Highlights
By The Associated Press - AP - Thu Sep 11, 4:57PM CDT
___
FDA panel backs Novo Nordisk injection for obesity
AP - Thu Sep 11, 4:42PM CDT
WASHINGTON (AP) — Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?
at The Street - Thu Sep 11, 3:10PM CDT
Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
at The Street - Thu Sep 11, 12:23PM CDT
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.
Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy
at The Street - Tue Sep 16, 8:48AM CDT
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
2 New Diet Drugs Coming Soon?
George Budwell, The Motley Fool - Motley Fool - Sat Sep 13, 1:05PM CDT
America's love of "supersized" everything has helped fuel an out-of-control obesity problem that is having dire consequences on human health and the economy. For instance, the CDC estimates that the annual medical cost of obesity in the U.S., as of...
Business Highlights
By The Associated Press - AP - Thu Sep 11, 4:57PM CDT
___
FDA panel backs Novo Nordisk injection for obesity
AP - Thu Sep 11, 4:42PM CDT
WASHINGTON (AP) — Federal health experts say a diabetes drug from Novo Nordisk should be approved for a new use in treating obesity.
FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 11, 3:46PM CDT
Source: Takeda Pharmaceuticals Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . (The FDA made the same...
How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?
at The Street - Thu Sep 11, 3:10PM CDT
Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.
FDA approves weight-loss drug Contrave
By MATTHEW PERRONE - AP - Thu Sep 11, 12:49PM CDT
WASHINGTON (AP) — U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.
Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised
at The Street - Thu Sep 11, 12:23PM CDT
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
Pharma Equities Technical Coverage - VIVUS, Auxilium Pharma, Depomed, Endo Intl., and Perrigo
PR Newswire - Wed Sep 10, 8:10AM CDT
On Tuesday, September 09, 2014, the NASDAQ Composite ended at 4,552.29, down 0.87%, the Dow Jones Industrial Average finished the day 0.57% lower at 17,013.87, and the S&P 500 closed at 1,988.44, down 0.65%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 739.32, down 0.31%, while the index has advanced 6.94% in the last three months. Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ: VVUS), Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Depomed Inc. (NASDAQ: DEPO), Endo International PLC (NASDAQ: ENDP), and Perrigo Company PLC (NYSE: PRGO). Free research on these five companies can be accessed at:
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Sean Williams, The Motley Fool - Motley Fool - Tue Sep 09, 8:45AM CDT
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech index by a full...
Critical Alerts For Mobileye NV, YPF, Boston Scientific, VIVUS and Juniper Networks Released By InvestorsObserver
PR Newswire - Thu Sep 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MBLY, YPF, BSX, VVUS and JNPR.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
VIVUS Acquires Certain Topamax Related Patents from J&J - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 4:00PM CDT
VIVUS, Inc. (VVUS) announced that it has acquired certain patents related to Topamax from Janssen Pharmaceuticals, Inc.
VIVUS buys topiramate-related patents from Janssen Pharmaceuticals
M2 - Tue Aug 26, 7:47AM CDT
Biopharmaceutical company VIVUS (NasdaqGS:VVUS) revealed on Monday the completion of the acquisition of a group of patents from Janssen Pharmaceuticals.
Vivus acquires patent rights to Qsymia ingredient
AP - Mon Aug 25, 7:37AM CDT
MOUNTAIN VIEW, Calif. (AP) — Vivus has acquired a group of patents covering one of the main ingredients behind its weight loss drug Qsymia from Janssen Pharmaceuticals.
VIVUS Announces Acquisition of Topiramate-Related Patents From Janssen Pharmaceuticals
Marketwire - Mon Aug 25, 6:00AM CDT
VIVUS, Inc. (NASDAQ: VVUS) today announced the acquisition of a group of patents from Janssen Pharmaceuticals, Inc. covering uses of topiramate as monotherapy and in combination with other pharmaceutical agents to treat a variety of medical conditions.
Biotech Investing: 3 Ways You're Doing It Wrong
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 24, 1:35PM CDT
Source: Felixioncool , Pixabay When it comes to industries that offer investors a higher than average risk-versus-reward scenario, biotech investing arguably takes the cake. Since the benchmark S&P 500 bottomed out in March 2009 the index...
Auxilium Posts Wider-than-Expected Loss, Outlook Maintained - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 1:10PM CDT
The share price of Auxilium Pharmaceuticals, Inc. (AUXL) fell 9.6% after the company announced its second-quarter results on Aug 7. However, share prices have however recovered approximately 3.1% thereafter.
VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 10:00AM CDT
VIVUS Inc. (VVUS) reported second quarter 2014 loss (excluding one-time items) of 25 cents per share.
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 8:20AM CDT
Orexigen Therapeutics, Inc. (OREX) reported a net loss of 21 cents per share in the second quarter of 2014.
